Review
Published on 23 Sep 2022
Targeting mitochondrial quality control of T cells: Regulating the immune response in HCC
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.993437
- 3,631 views
- 5 citations
Type at least 3 characters
1,766 articles
Articles
Correction
Published on 22 Sep 2022
Corrigendum: TPX2 enhanced the activation of the HGF/ETS-1 pathway and increased the invasion of endocrine-independent prostate carcinoma cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1032265
- 903 views
Original Research
Published on 21 Sep 2022
Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.994333
- 5,968 views
- 10 citations
Brief Research Report
Published on 21 Sep 2022
Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.987643
- 1,772 views
- 3 citations
Clinical Trial
Published on 21 Sep 2022
Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: The REALIZE study
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.900010
- 2,972 views
- 5 citations
Case Report
Published on 20 Sep 2022
Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.915502
- 1,666 views
- 2 citations
Original Research
Published on 20 Sep 2022
Glycosyltransferase-related long non-coding RNA signature predicts the prognosis of colon adenocarcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.954226
- 2,497 views
- 4 citations
Original Research
Published on 20 Sep 2022
KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.976292
- 2,529 views
- 4 citations
Brief Research Report
Published on 20 Sep 2022
Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: The INSPECT experience (2008-2020)
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.951662
- 2,939 views
- 14 citations
Review
Published on 20 Sep 2022
APOBEC3B: Future direction of liver cancer research
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.996115
- 3,767 views
- 3 citations
Original Research
Published on 15 Sep 2022
Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1/2, NF-ÎşB and beta-catenin pathways
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.873447
- 3,201 views
- 6 citations
Review
Published on 14 Sep 2022
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.996438
- 5,601 views
- 10 citations
Review
Published on 14 Sep 2022
Does the shape of the electric pulse matter in electroporation?
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.958128
- 6,626 views
- 17 citations
Review
Published on 14 Sep 2022
Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.892212
- 5,613 views
- 5 citations
Original Research
Published on 14 Sep 2022
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.953013
- 7,197 views
- 9 citations
Original Research
Published on 12 Sep 2022
ADAMDEC1 accelerates GBM progression via activation of the MMP2-related pathway
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.945025
- 2,601 views
- 2 citations